Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke

NCT06639360 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-08-02
Last updated
2025-12-04

Condition(s) studied

Ischemic Stroke, AcuteEndovascular Thrombectomy

Investigational drug(s) / intervention(s)

Transcranial Magnetic Stimulation ActiveTranscranial Magnetic Stimulation Sham

Transcranial Magnetic Stimulation Active: The patients will be treated with cTBS and usual medical treatment after endovascular treatment

Transcranial Magnetic Stimulation Sham: The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment

Study summary

This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old. 2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery. 3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy. 4. Pre-stroke mRS score is ≤1. 5. NIHSS score before thrombectomy is between 6 and 25. 6. With vascular recanalization of mTICI \> 2b/3. 7. Informed consent form signed. Exclusion Criteria: 1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.; 2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys; 3. Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention; 4. Head CT/MRI suggests acute cerebral infarction in both sides; 5. Patients who are pregnant or breastfeeding; 6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up; 7. Patients with other severe diseases resulting in an expected survival of less than 90 days; 8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition; 9. Patients who cannot cooperate with informed consent.

Primary outcome measure(s)

  • Changes of infarct volumes from baseline to Day 5 — 5 days after enrollment
  • Death — The first 5 days after enrollment
  • NIHSS at Day 5 — 5 days after enrollment

Trial sites (1)

FacilityCityRegionStatus
Xijing Hospital Xi'an Shaanxi Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06639360 on ClinicalTrials.gov ↗ ← All trials in China